Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine

References

• Department of Human and Health Services 2011 . Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents . Retrieved from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Egger , M. 2007 . Outcomes of ART in resource-limited and industrialized countries . 14th Conference on Retroviruses and Opportunistic Infections . Los Angeles , CA , , USA . Feb 25–28, 2007; 22 Abstract retrieved from http://www.retroconference.org/2007/data/files/webpage_for_CROI.htm
   Google Scholar
• Egger , M. , May , M. , Chene , G. , Phillips , A.N. , Ledergerber , B. , Dabis , F. and Sterne , J.A. 2002 . Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies . Lancet , 360 : 119 – 129 .
   PubMed Web of Science ®Google Scholar
• Lawn , S.D. , Badri , M. and Wood , R. 2005 . Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort . AIDS , 19 : 2109 – 2116 .
   PubMed Web of Science ®Google Scholar
• Lawn , S. , Myer , L. , Bekker , L.G. and Wood , R. 2006 . CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa . BMC Infectious Diseases , 6 : 59 – 66 .
   PubMed Web of Science ®Google Scholar
• Lawn , S.D. , Myer , L. , Orrell , C. , Bekker , L.G. and Wood , R. 2005 . Early mortality among adults accessing a community-based antiretroviral service in South Africa: Implications for programme design . AIDS , 19 : 2141 – 2148 .
   PubMed Web of Science ®Google Scholar
• May , M.T. , Sterne , J.A. , Costagliola , D. , Sabin , C.A. , Phillips , A.N. , Justice , A.C. and Egger , M. 2006 . HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: A collaborative analysis . Lancet , 368 : 451 – 458 .
   PubMed Web of Science ®Google Scholar
• May , M. , Sterne , J.A. , Sabin , C. , Costagliola , D. , Justice , A.C. , Thiebaut , R. and Egger , M. 2007 . Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies . AIDS , 21 : 1185 – 1197 .
   PubMed Web of Science ®Google Scholar
• Molina , J.M. , Andrade-Villanueva , J. , Echevarria , J. , Chetchotisakd , P. , Corral , J. , David , N. and McGrath , D. 2008 . Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study . Lancet , 372 : 646 – 655 .
   PubMed Web of Science ®Google Scholar
• Molina , J.M.M. , Andrade-Villanueva , J.M. , Echevarria , J.M. , Chetchotisakd , P.M. , Corral , J.M. , David , N.F. ,  for the CASTLE Study Team ( 2010 ). Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study . JAIDS , 53 , 323 – 332 .
   Google Scholar
• Robbins , G.K. , Spritzler , J.G. , Chan , E.S. , Asmuth , D.M. , Gandhi , R.T. , Rodriguez , B.A. and Pollard , R.B. 2009 . Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384 . Clinical Infectious Diseases , 48 : 350 – 361 .
   PubMed Web of Science ®Google Scholar